Form 4: Protara Therapeutics Director Cynthia Smith Granted 24,000 Stock Options

Protara Therapeutics, Inc. Director Cynthia Smith was granted 24,000 stock options with an exercise price of $3.26, vesting over one year or upon a change of control.

Summary

• Cynthia Smith, a Director of Protara Therapeutics, Inc. (TARA), was granted 24,000 stock options.
• The transaction date for the grant was June 12, 2025.
• Each stock option has an exercise price of $3.26.
• The options will vest in full on the first anniversary of the grant date, which is June 12, 2026, provided continuous service as a Board member.
• Alternatively, the options will vest in full upon a Change of Control.
• The expiration date for these stock options is June 11, 2035.
• Following this transaction, Cynthia Smith beneficially owns 24,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is a positive governance practice. However, it is a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of stock options aligns the interests of Director Cynthia Smith with those of the shareholders, as the value of her compensation is tied to the company's stock performance.
• This is a standard form of compensation for directors, indicating routine corporate governance practices.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, as new shares would be issued.

Future Outlook

The document does not contain specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the vesting schedule of the granted options.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to incentivize long-term commitment and align management interests with shareholder value creation. This filing reflects a routine compensation event for a board member.

Corporate Governance

Related Party Transactions

• The grant of stock options to Cynthia Smith, a Director of Protara Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also improved alignment of director incentives with shareholder value creation.
• Employees: No direct impact mentioned in this filing.

Next Steps

• The stock options are scheduled to vest on June 12, 2026, subject to the director's continuous service or a change of control.

Key Dates

Keywords

Protara Therapeutics, TARA, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting